C. Glenn Begley
Head of Biology*
C. Glenn Begley MBBS (MD-equivalent), PhD, FRACP, FRCPA, FRCPath, FAHMS is a physician and hematologist/medical oncologist, with a PhD in cell and molecular biology.
For 4 years (until March 2021) he served as inaugural CEO of BioCurate, a joint initiative of Monash and Melbourne Universities to achieve impact from their biomedical research.
He served as Chief Scientific Officer at Akriveia Therapeutics (now Xilio), California (2016-2017), and TetraLogic Pharmaceuticals, Pennsylvania (2012-2016), and as non-Executive Director at Oxford BioTherapeutics (2012-2017). He was Vice-President and Global Head of Hematology/Oncology Research at Amgen, Thousand Oaks, California (2002-2012), with responsibility at Amgen’s 5 research sites.
His scientific responsibilities included Amgen marketed products (filgrastim, pegfilgrastim, erythropoietin, darbepoetin alpha, palifermin, ancestrim, romiplostim, denosumab). Over 25 clinical-stage molecules emerged from his group including fully human monoclonal antibodies, small molecules, protein ligands, antibody-drug conjugates. He was also the internal oncology advocate for in-licensed molecules including, the bi-specific T-cell engager (BiTE) blinatumomab, and the oncolytic virus talimogene laherparepvec (T-Vec).
While at Amgen he highlighted the issue of research integrity and scientific reproducibility. He has made multiple presentations on this subject including to President Obama’s Science Council, the White House, US National Institutes of Health, US Academies of Science, US National Institute of Standards and Technology, Wellcome Trust, NHMRC, and numerous Universities, Research Institutes and companies.
Prior to Amgen, he had over 20 years of clinical and research experience in medical oncology/hematology. His early research first described human G-CSF. In later clinical studies he first demonstrated that G-CSF-“mobilized” blood stem cells hastened hematopoietic recovery compared with bone marrow transplantation (so called “stem cell transplantation”).
His honors include being elected as the first Foreign Fellow to the American Society of Clinical Investigation (2000), the Association of American Physicians (2008), to the Research “Hall of Fame” at his alma mater, the Royal Melbourne Hospital (2014), to the Australian Academy of Health and Medical Sciences (2014).
He has published over 200 papers that have been widely cited (~25,000 citations; h-index 77; i10-index 188, source Google Scholar, August 2020). His TED-x seminar “The Complex Biology of Cancer” has >100,000 views.